Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China · Delayed Price · Currency is CNY 3.260
+0.040 (1.24%)
Sep 7, 2026, 3:04 PM CST
SHE:002589 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,792 | 4,779 | 4,444 | 4,920 | 6,165 | 5,881 | |
Market Cap Growth | 12.50% | 7.54% | -9.67% | -20.19% | 4.83% | -24.86% |
Enterprise Value | 4,361 | 6,401 | 7,022 | 3,501 | 7,785 | 11,382 |
Last Close Price | 3.26 | 3.22 | 2.96 | 3.24 | 4.08 | 3.88 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 530.13 | 297.39 | 361.52 | 242.17 | - | 44.83 |
Forward PE | - | 8.02 | 8.02 | 8.02 | 8.02 | 8.45 |
PS Ratio | 0.67 | 0.66 | 0.56 | 0.61 | 0.50 | 0.28 |
PB Ratio | 0.88 | 0.88 | 0.78 | 0.87 | 1.07 | 0.61 |
P/TBV Ratio | 1.03 | 1.03 | 0.90 | 1.04 | 1.33 | 0.91 |
P/FCF Ratio | 178.66 | - | 90.29 | - | 17.51 | - |
P/OCF Ratio | - | 347.35 | 27.64 | 59.67 | 11.79 | 13.28 |
PEG Ratio | - | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 0.61 | 0.88 | 0.88 | 0.44 | 0.63 | 0.54 |
EV/EBITDA Ratio | 16.56 | 28.90 | 32.50 | 26.75 | 46.91 | 10.22 |
EV/EBIT Ratio | 31.62 | 88.58 | 351.63 | - | - | 13.99 |
EV/FCF Ratio | 162.57 | - | 142.65 | - | 22.11 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.95 | 0.85 | 1.15 | 1.21 | 0.70 | 0.47 |
Debt / EBITDA Ratio | 19.66 | 20.57 | 30.03 | 50.40 | 22.86 | 4.01 |
Debt / FCF Ratio | 193.04 | - | 133.76 | - | 11.37 | - |
Net Debt / Equity Ratio | -0.10 | 0.16 | 0.28 | 0.31 | -0.23 | 0.00 |
Net Debt / EBITDA Ratio | -2.19 | 3.88 | 7.41 | 13.47 | -8.05 | -0.03 |
Net Debt / FCF Ratio | -21.39 | -65.87 | 32.50 | -8.17 | -3.79 | 1.92 |
Asset Turnover | 0.43 | 0.48 | 0.49 | 0.46 | 0.55 | 0.72 |
Inventory Turnover | 8.85 | 9.00 | 7.66 | 6.96 | 7.07 | 6.92 |
Quick Ratio | 1.00 | 1.00 | 1.03 | 0.96 | 0.93 | 1.08 |
Current Ratio | 1.08 | 1.09 | 1.12 | 1.07 | 1.03 | 1.25 |
Return on Equity (ROE) | 0.79% | 0.79% | 0.53% | 0.56% | -22.52% | 3.78% |
Return on Assets (ROA) | 0.52% | 0.30% | 0.08% | -0.30% | -0.30% | 1.74% |
Return on Invested Capital (ROIC) | 2.08% | 1.06% | 0.27% | -1.43% | -1.54% | 5.47% |
Return on Capital Employed (ROCE) | 2.40% | 1.30% | 0.30% | -1.40% | -1.90% | 8.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.19% | 0.34% | 0.28% | 0.41% | -29.70% | 2.23% |
FCF Yield | 0.56% | -0.27% | 1.11% | -4.39% | 5.71% | -0.31% |
Dividend Yield | 0.06% | 0.06% | 0.37% | 0.40% | - | 0.23% |
Payout Ratio | 1172.00% | 1085.79% | 1618.06% | 992.70% | - | 241.13% |
Buyback Yield / Dilution | -31.25% | -30.73% | 18.31% | -1.93% | -1.30% | -0.40% |
Total Shareholder Return | -31.19% | -30.66% | 18.68% | -1.53% | -1.30% | -0.17% |